Despite the introduction of new nucleos(t)ide analogues in recent years, peginterferon is still recommended as a potential first-line treatment option by current practice guidelines for the management of chronic hepatitis B. Peginterferon offers the advantage of higher sustained off-treatment response rates compared to nucleos(t)ide analogues because of its immunomodulatory effects. Sustained transition to the inactive hepatitis B surface antigen (HBsAg) carrier state can be achieved in about 30% of hepatitis B e antigen (HBeAg)–positive patients and 20% of HBeAg-negative patients. Recent studies have focused on identification of pretreatment and on-treatment factors that allow the selection of patients who are likely to achieve a sustained response to peginterferon therapy in order to avoid the side-effects and costs associated with unnecessary treatment. Future studies need to address whether specific virologic benchmarks can guide individualized decisions concerning therapy continuation and whether peginterferon combined with new potent nucleos(t)ide analogues improves treatment outcomes.
European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227–242. CrossRef
Wong DK, Cheung AM, O’Rourke K , et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312–323. PubMed
•• Buster EH, Flink HJ, Cakaloglu Y , et al.: Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135:459–467. This report describes the durability of HBeAg loss induced by PEG-IFN therapy for HBeAg-positive CHB. CrossRefPubMed
Fung SK, Lok AS: Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004, 40:790–792. PubMed
Wai CT, Chu CJ, Hussain M , et al.: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002, 36:1425–1430. PubMed
•• Buster EH, Hansen BE, Lau GK , et al.: Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002–2009. This important study provides a decision rule for prediction of response to PEG-IFN therapy at baseline based on the two largest PEG-IFN trials for HBeAg-positive CHB. CrossRefPubMed
Nguyen T, Desmond P, Locarnini S: The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009, 3:S5–S15. CrossRef
• Fried MW, Piratvisuth T, Lau GK , et al.: HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428–434. The potential of quantitative HBeAg for predicting response to PEG-IFN therapy in HBeAg-positive patients is investigated in this study. CrossRefPubMed
Lau GKK, Marcellin P, Brunetto M , et al.: On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009, 50:S333. CrossRef
•• Marcellin P, Bonino F, Lau GK , et al.: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136:2169–2179. This important study describes the durability of response to PEG-IFN therapy in HBeAg-negative patients. CrossRefPubMed
Farci P, Marcellin P, Lu ZM , et al.: On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon alpha-2a (40 kDa) (Pegasys(R)). J Hepatol 2005, 42:S175.
• Brunetto MR, Moriconi F, Bonino F , et al.: Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141–1150. This study investigates the role of quantitative HBsAg in prediction of sustained response to PEG-IFN therapy. CrossRefPubMed
Rijckborst V, Hansen BE, Cakaloglu Y , et al.: Early prediction of sustained response to peginterferon alfa-2a in HBeAg-negative patients: The role of on-treatment HBsAg and HBV DNA levels. J Hepatol 2010, 52:S4–S5. CrossRef
Rijckborst V, Ter Borg MJ, Cakaloglu Y , et al.: A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010, 105:1762–1769.
Chan HL, Wong VW, Chim AM , et al.: Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007, 12:815–823. PubMed
Lampertico P, Vigano M, Di Costanzo G , et al.: Extended (2 years) treatment with peginterferon alfa-2a [40 kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010, 52:S45. CrossRef
- The Role of Interferon in Hepatitis B Therapy
Harry L. A. Janssen
- Current Science Inc.
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II